CYRX Cryoport, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1124524 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.8%
TTM net income YoY-157.9%
TTM EPS YoY-178.6%
Revenue 3-yr CAGR-6.6%
Net income 3-yr CAGR—
Margins
Gross margin46.9%
Operating margin-20.0%
Net margin-21.5%
FCF margin-9.8%
EBITDA margin-6.6%
Returns
ROE-8.3%
ROA-5.4%
ROIC (approx.)-13.2%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets35.6%
Debt / equity0.00x
Current ratio2.04x
Interest coverage-18.32x
Cash quality & payout
Operating cash flow / net income-0.27x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue15.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $176.18M | $156.77M |
| Cost of revenue | $93.12M | $87.11M |
| Gross profit | $83.05M | $69.66M |
| R&D expense | $17.04M | $17.71M |
| SG&A expense | $102.82M | $109.81M |
| Operating income | -$36.81M | -$121.67M |
| Interest expense | $2.36M | $3.98M |
| Pretax income | -$32.17M | -$104.35M |
| Income tax | $1.80M | $359,000 |
| Net income | $78.30M | -$114.76M |
| EBITDA | -$9.09M | -$90.91M |
| EPS (basic) | 1.40 | -2.49 |
| EPS (diluted) | 1.40 | -2.49 |
| Weighted avg. shares (diluted) | 50.07M | 49.35M |
| Balance sheet | ||
| Cash & equivalents | $250.49M | $34.14M |
| Short-term investments | $160.71M | $216.46M |
| Receivables | $33.36M | $25.30M |
| Inventory | $23.19M | $21.48M |
| Current assets | $476.17M | $341.57M |
| PP&E, net | $85.45M | $80.01M |
| Goodwill | $22.40M | $20.57M |
| Intangibles | $138.08M | $147.93M |
| Total assets | $764.99M | $703.49M |
| Current liabilities | $219.02M | $64.56M |
| Total liabilities | $262.35M | $301.59M |
| Shareholders' equity | $502.64M | $401.90M |
| Shares outstanding | 49.85M | 49.91M |
| Cash flow statement | ||
| Operating cash flow | -$8.58M | -$16.32M |
| Capital expenditure | $16.44M | $17.25M |
| Free cash flow | -$25.02M | -$33.58M |
| Investing cash flow | $250.32M | $176.81M |
| Financing cash flow | -$21.07M | -$161.53M |
| Depreciation & amortization | $27.71M | $30.76M |
| Stock-based compensation | $10.07M | $16.57M |
| Share buybacks | $10.01M | — |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.